Anti-angiogenic Agents Plus Anti-PD-1 Antibodies for uHCC

Cancer shared this article with you from Inoreader Anti-angiogenic Agents Plus Anti-PD-1 Antibodies for uHCC Via MedWorm Cancer & Oncology Clinical Trials Condition:   Hepatocellular Carcinoma Intervention:   Drug: Anti-angiogenic agents plus anti-PD-1/PD-L1 antibodies Sponsor:   Shanghai Zhongshan Hospital Recruiting (Source: ClinicalTrials.gov) View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.